Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-714-1 | CAS number: 16669-27-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 001
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- CD rats were administered Docosan-1-ol (Behenyl alcohol) by oral gavage for 26 weeks at doses of 0, 10, 100, or 1000 mg/kg bw/day.
- GLP compliance:
- yes
- Remarks:
- Huntingdon Life Sciences Ltd (Suffolk, England)
- Limit test:
- no
Test material
- Reference substance name:
- Docosan-1-ol
- EC Number:
- 211-546-6
- EC Name:
- Docosan-1-ol
- Cas Number:
- 661-19-8
- Molecular formula:
- C22H46O
- IUPAC Name:
- docosan-1-ol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited (Margate, Kent, England)
- Age at study initiation: 21 to 28 days
- Housing: stainless-steel cages, male and female rats were separated and housed 5 per cage
- Diet: expanded rodent diet without added antibiotic or other chemotherapeutic or prophylactic agent, ad libitum
- Water: tap water, ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21°C
- Humidity (%): 55%
- Photoperiod (hrs dark / hrs light): 12 hours/12 hours
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1% w/w aqueous Tween 80
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The required amount of test item was weighed into a glass container and heated (approximately 80°C) until molten using an electric mantle.
An appropriate volume of vehicle (1% Tween 80) was heated in a water bath to at least 75°C and then combined with the molten behenyl alcohol under continuous magnetic stirring, to a concentration of 20% behenyl alcohol. The resulting suspension was slowly cooled, with homogenization to a temperature of below 60°C, and then further cooled in a water bath to a temperature of 30°C. The 20% suspension was prepared once each week. Lower concentrations were prepared on the day of use by dilution of the 20% suspension with 1% w/w aqueous Tween 80.
VEHICLE
- aqueous Tween 80
- Amount of vehicle (if gavage): 1%
Animals received the test material or vehicle control formulations by gavage, at a volume-dosage of 5 mL/kg bw, using an 8 or 10 choke rubber catheter. The volume administered was calculated from body weights measured immediately before each administration. - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 26 weeks
- Frequency of treatment:
- 7 days a week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 20 male and 20 female per dose (main study)
10 male and 10 female per dose (toxicokinetic study) - Control animals:
- yes, concurrent vehicle
- Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: prestudy, weekly for the duration of the study, and at necropsy
FOOD CONSUMPTION
- calculated weekly throughout the treatment periods
FOOD EFFICIENCY:
- Weekly group mean food conversion efficiencies were calculated for the first 14 weeks of the study
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: prestudy, and during weeks 12 and 25 of the study
HAEMATOLOGY: Yes
- Time schedule for collection of blood: during weeks 14 and 26
- Anaesthetic used for blood collection: Yes, anesthetized with halothane/nitrousoxide at time of sampling
- Animals fasted: Yes
- How many animals: 10 rats/sex/dose
- Parameters checked: hemoglobin concentrations, erythrocyte count, total and differential leukocyte count, platelet count, mean cell hemoglobin concentration, mean cell hemoglobin, morphology and unusual cell types, including normoblasts, anticoagulant and prothrombin time was measured
Blood samples were obtained from 6 (3 males and 3 females) nonfasted satellite rats on Day 1 and during Weeks 13 and 26 at 0.5, 1, 2, 4, 8, and 24 h after dosing
CLINICAL CHEMISTRY: Yes
- Parameters checked: alkaline phosphatase activity, alanine amino-transferase, aspartate amino-transferase,gamma-glutamyl transpeptidase, glucose, total bilirubin, total cholesterol, urea, total triglyceride, total protein,and electrolyte levels: Na, K, Cl, and C, inorganic phosphorus and electrophorectic protein, creatine
URINALYSIS: Yes
- Time schedule for collection of urine: during weeks 12 and 25
- Metabolism cages used for collection of urine: No
- Animals fasted: nonfasted waterdeprived
- Parameters checked: urine pH and protein, glucose, ketones, bilirubin, urobilinogen, blood, urine-specific gravity, the appearance and volume of urine
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- detailed examination of the external features and orifices, the neck and associated tissues, and the cranial, thoracic, abdominal, and pelvic cavities, and their viscera
HISTOPATHOLOGY: Yes
- adrenals, brain, eyes and optic nerve, femur, heart, kidneys, liver, lungs, seminal vesicles, spinal cord, stomach, thyroid, and uterus - Statistics:
- For organ weights and body weight changes, homogeneity of variance was evaluated by Bartlett’s test. Whenever this was found to be statistically significant, a Behrens-Fisher test was used to perform pairwise comparisons; otherwise, a Dunnett’s test was used. Fisher’s exact test was applied as a two-tailed test, where appropriate, to the distribution of macroscopic or microscopic pathological entities. Unless stated, group mean values or incidences for the treated groups were not significantly different from those for the controls (P>0.05). The significance of intergroup differences in hematology (excluding the incidence of morphological abnormalities evident on the blood smears for rats), blood chemistry, and urinalysis (volume, pH, and specific gravity only) was assessed by Student’s t test using a pooled error variance.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One male receiving 100 mg/kg/day died during Week 25.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Toxikokinetic study:
Blood sample results were obtained from satellite animals on Day 1, and during Weeks 13 and 26 of the study. The maximum mean plasma concentration (Cmax) occurred 1 h after dosing in all males and in the majority of the females. During Week 13, females in the 100 and 1000 mg/kg bw/day dose level groups reached the Cmax at 0.5 h after dosing. 24 hours after dosing, plasma concentrations of behenyl alcohol in animals from the 10 and 100 mg/ kg bw/day dose group were generally below the limit of quantification (<10 ng/ml). In animals treated with 1000 mg/kg bw/day, mean plasma concentrations of behenyl alcohol were quantifiable on each sampling day, and these values ranged from 203.68 to 528.82 ng/mL throughout the duration of the study.
Area under the curve (AUC24) values ranged from 1043.8 to 3196.0 ng x h/mL in males and females treated with 1000 mg/kg bw/day during the study. Generally, no statistically significant sex-related differences occurred in any of the dose groups. However, statistically significant differences (P=0.040) in AUC24 values, 24 h after dosing, were observed between males and females treated with 10 and 1000 mg/kg bw/day on Day 1 and during Week 13 of the study, respectively. On Day 1, AUC24 values of 96.4 and 154.8 ng x h/mL were obtained in male and females treated with 10 mg/kg bw/day, respectively, while AUC24 values of 2797.0 and 1043.8 ng x h/ml were obtained in males and females treated with 1000 mg/ kg bw/day, respectively. The rate and extent of systemic exposure of rats to behenyl alcohol, characterized by the Cmax and AUC24, respectively, on Day 1 and during Weeks 13 and 26 of the study increased with increasing dose level; however, these increases were less than the proportionate dose increment, and there was statistically significant evidence of non-proportionality on each of the sampling days (P=0.056).
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: highest dose tested
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Maximum Mean Plasma concentrations of Behenyl Alcohol in rats and the areas under the mean plasma behenyl alcohol concentration time curves estimated up to 24 h postdose on Day 1 and during weeks 13 and 26 of the study
Day 1 | Week 13 | Week 26 | ||||
Dose level (mg/kg bw/day) | Males | Females | Males | Females | Males | Females |
Maximum mean plasma concentration (Cmax) (ng/mL) | ||||||
10 | 31.16 (11.94) | 49.00 (12.26) | 53.28 (23.68) | 42.66 (17 .44) | 93.08 (49.06) | 46.13 (23.26) |
100 | 179.96 (109.07) | 117.63 (25.88) | 306.92 (207.29) | 160.25 (83.92) | 153.14 (34.42) | 151.76 (40.43) |
1000 | 292.74 (47.53) | 203.68 (30.43) | 525.72 (232.90) | 414.91 (82.85) | 526.40 (160.22) | 528.82 (171.70) |
Area under the curve (AUC24)(ng x h/mL) | ||||||
10 | 96.4 (21.0) | 154.8 (19.2) | 271.5 (64.6) | 257.7 (71.4) | 290.0 (73.0) | 127.8 (55.7) |
100 | 766.6 (89.7) | 720.1 (161.0) | 731.7 (180.6) | 345.2 (106.9) | 1072.7 (372.2) | 378.9 (70.5) |
1000 | 1858.0 (253.0) | 1296.7 (186.6) | 2797.0 (539.7) | 1043.8 (102.9) | 3196.0 (433.7) | 2254.9 (442.7) |
Numbers in parentheses represent standard deviations and standard errors of the Cmax and AUC24, respectively.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.